Overview
Myqorzo is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), a condition in which the heart muscle becomes abnormally thick and obstructs blood flow. Before starting treatment, a person must undergo echocardiogram assessments of left ventricular ejection fraction (LVEF), which measures how well the heart pumps blood. These assessments must continue while taking the drug. Myqorzo should not be started in individuals with an LVEF below 55 percent. Due to the risk of heart failure, Myqorzo is only available through a risk evaluation and mitigation strategy (REMS) program. Myqorzo is also known by its drug name, aficamten.

Myqorzo is a cardiac myosin inhibitor. It works by reducing excessive contractions of the heart muscle, which can help improve blood flow and relieve symptoms of oHCM.

How do I take it?
Prescribing information states that Myqorzo is taken orally once daily. Dosing may be adjusted based on echocardiographic findings and clinical symptoms. The drug should be taken exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Myqorzo include hypertension (high blood pressure).

Rare but serious side effects may include heart failure due to reduced systolic function (the heart’s ability to pump), especially if the left ventricular ejection fraction drops below safe levels.

For more information about this treatment, visit:
Label: Myqorzo — Aficamten Tablet, Film Coated — DailyMed